! As always, Thank you for this updated information. Time to dig in and do my DD!
Alibaba
BABA
Micron Technology
MU
NVIDIA
NVDA
Cisco
CSCO
Netflix
NFLX
US Stock MarketDetailed Quotes
GRAL Grail
- 55.020
- +2.440+4.64%
Close Feb 14 16:00 ET
- 57.000
- +1.980+3.60%
Post 20:01 ET
1.85BMarket Cap-0.86P/E (TTM)
55.320High48.900Low3.16MVolume50.300Open52.580Pre Close167.75MTurnover9.40%Turnover RatioLossP/E (Static)33.60MShares55.32052wk High0.71P/B1.85BFloat Cap12.33052wk Low--Dividend TTM33.60MShs Float55.320Historical High--Div YieldTTM12.21%Amplitude12.330Historical Low53.096Avg Price1Lot Size
Grail Stock Forum
Sign in to post a comment
$Grail (GRAL.US)$ garbage
2
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
59
17
8
4
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
1
$Illumina (ILMN.US)$ botched the acquisition of $Grail (GRAL.US)$ after the move was banned by european authorities and has finished divesting as GRAL just opened shop on stock markets very recently as a separate entity from ILMN. with this shareholders might start to pour money back into Illumina which is clearly undervalued by any metric you throw at it it's not a dead business so there's some money to be made here you can look at the chart recently ...
5
$Grail (GRAL.US)$ why circuit breaker?
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
EnorrisBEAST : looking good
别叫我买股票 OP EnorrisBEAST : seem like something brewing